Explore the Agenda

8:30 am Check-In, Coffee & Light Breakfast

8:50 am Chair’s Opening Remarks

Senior Principal Scientist, UCB

Moving Beyond TfR1 to Unlock New Routes for Targeted Brain Delivery

9:00 am Panel Discussion: Beyond TfR1: Evaluating Next‑Generation BBB Receptors for Systemic Biologic Delivery to the Brain

Senior Principal Scientist, UCB
Principal Investigator, Brain Targeting Program, WYSS Institute, Harvard Medical School
Principal Investigator, Rowland Institute, Harvard University
Lab Head & Research Project Leader, Roche
  • Which alternative BBB receptors (e.g. CD98hc, Ca4, ALPL, glycan and others) show the most promise beyond TfR1 for achieving sufficient brain uptake without compromising safety or peripheral PK?
  • How can we optimize receptor affinity, valency, and trafficking profiles to balance efficient transcytosis with minimal lysosomal degradation or target-mediated clearance, as it pertains to payloads?
  • Improving brain specific and cell specific targeting
  • How should developers prioritize receptor selection based on modality (e.g. antibodies, enzymes, oligonucleotides) and indication-specific needs for brain distribution and cellular targeting?

9:30 am Advancing Alternative BBB Shuttle Platforms Through Antibody Discovery Structural Biology & Imaging Validation

Vice President, Biotherapeutic Discovery, Lundbeck
  • Designing novel receptor mediated transcytosis shuttles to expand CNS delivery beyond transferrin based systems
  • Linking antibody affinity epitope binding and intracellular trafficking to optimize brain exposure and release
  • Integrating antibody discovery datasets with structural biology to improve shuttle performance
  • Using brain imaging approaches to quantify distribution and validate delivery efficiency across regions

10:00 am Morning Break & Refreshments

Track 1: Technology & Platform Development

Designed for:

Drug delivery, platform, biologics, antibody, oligonucleotide, vector, protein engineering and chemistry teams developing the next generation of CNS delivery technologies.

Explore the engineering, chemistry and design principles underpinning brain shuttles, capsids, conjugates and device-enabled delivery systems to improve BBB transport, brain exposure and delivery efficiency.

Chaired by –

Executive Director, Drug Delivery & Devices DDCS, Eli Lilly
Executive Director, Drug Delivery & Devices DDCS, Eli Lilly

Capsid & Vector Engineering for Efficient Gene Therapy Delivery Across the BBB

11:00 am Translating ALPL-Mediated BBB Transport into the Clinic: Next-Generation Capsid Engineering for CNS Gene Therapy

Vice President, Gene Therapy, Voyager Therapeutics
  • Translate ALPL-mediated BBB transport from platform discovery into clinical reality, supported by early human data and safety readouts
  • Position ALPL as a differentiated, cross-species BBB target with improved translational relevance beyond legacy approaches such as TfR1
  • Demonstrate how strong NHP validation of ALPL-targeting capsids enables progression into clinical CNS programs, including tau knockdown in Alzheimer’s disease
  • Showcase next-generation capsid engineering strategies that enhance brain-wide transduction, reduce off-target effects, and improve systemic gene therapy delivery

11:30 am Advancing Chronic Intrathecal Delivery via Implantable Port-Catheter Systems to Improve CNS Therapeutic Access & Patient Experience

Head of Device Clinical, Biogen
Head of IDU Device Development & Manufacturing, Biogen
  • Introducing the design and functionality of implantable intrathecal port‑catheter systems enabling repeat access to cerebrospinal fluid for CNS therapeutic delivery
  • Evaluating how device-enabled delivery can reduce reliance on repeated lumbar punctures and improve patient experience adherence and long-term feasibility
  • Sharing clinical progress and learnings from ongoing studies assessing safety performance and real-world usability of implantable intrathecal delivery platforms
  • Exploring the future role of integrated drug-device solutions in scaling antisense oligonucleotide and advanced therapy delivery across CNS indications

12:00 pm Building a Translational Roadmap for Next-Generation CNS Gene Therapies with TfR1 CapX

Director, Nonclinical & Translational Research, Apertura Gene Therapy
  • Applying TfR1 CapX to enable broad CNS delivery of novel therapeutic modalities, including the CHARM epigenetic editing platform being advanced for prion disease in collaboration with the Broad Institute
  • Demonstrating the versatility of TfR1 CapX across payload modalities while maintaining efficient brain and spinal cord exposure following intravenous administration
  • Developing quantitative translational frameworks that connect biodistribution, receptor engagement, and target knockdown data to clinically relevant dose selection strategies
  • Navigating regulatory expectations for first-in-class receptortargeted CNS delivery platforms and establishing a repeatable pathway for future rare disease and neurodegenerative programs

Track 2: Biology & Implementation

Designed for:

Neuroscience, biology, pharmacology, DMPK, PKPD and translational development teams seeking to evaluate, implement and de-risk CNS delivery approaches within therapeutic programs.

Explore biodistribution, target engagement, in vitro and in vivo models, dose translation, safety assessment and disease-specific case studies to understand how delivery technologies perform in real-world development settings.

Chaired By –

Director - Gene Therapy Program Lead, Deerfield

Case Studies of Testing Delivery Systems Within Disease Context

11:00 am Enabling Targeted Oligonucleotide Delivery to CNS for the Treatment of Neurological Pathologies

Director, Neuromuscular Research, Dyne Therapeutics
  • We have developed a TfR1 mediated delivery platform capable of transporting therapeutic oligonucleotides to both muscle and the CNS
  • This delivery platform has translated into clinically meaningful functional improvements in neuromuscular diseases, including DMD and DM1
  • In the CNS, our approach achieves broad and homogeneous brain distribution of oligonucleotide payloads, reaching deep brain regions that are inaccessible via intrathecal administration

11:30 am Challenges & Opportunities in Treatment of CNS Tumors

Research Fellow, Drug Delivery Sciences, Abbvie
  • CNS tumors, including newly diagnosed glioblastoma (GBM) and brain metastases, represent a significant commercial opportunity in an area of urgent unmet medical need. The incidence of brain metastases is increasing, in part because advances in treatment for cancers such as colorectal, pancreatic, breast, and lung cancer are extending patient survival and allowing more time for disease to spread to the brain
  • Many promising anticancer molecules are under development, but achieving effective concentration without causing toxicity remains a daunting challenge because of the blood brain barrier
  • We compare several strategies for drug delivery to the brain for the treatment of CNS tumors, delineate their respective advantages and limitations, and assess the outstanding challenges that remain to be addressed, including technical, adoption-related, and supply chain-related barriers

12:00 pm Identifying Novel Blood-Brain Barrier Transport Pathways Beyond TfR and CD98 for CNS Drug Delivery

Investigator, Novartis
  • Evaluating the limitations of current receptor-mediated shuttle approaches
  • Discovering and validating novel BBB transport mechanisms for therapeutic delivery
  • Developing screening strategies to identify high-potential shuttle targets
  • Translating emerging shuttle candidates from preclinical evaluation into clinical development

12:30 pm Lunch & Networking

Track 1: Technology & Platform Development

Advances in Device-Mediated Delivery Bypassing the BBB

1:30 pm Targeted Blood Brain Barrier Opening Using Focused Ultrasound to Enable Spatially Precise CNS Drug Delivery Without Molecular Re-Engineering

Founding Scientist, Lotus Neuroscience
  • Demonstrating transient and region-specific BBB opening using microbubble-mediated focused ultrasound with reproducible safety across 300+ patients
  • Enabling localized delivery of biologics, oligonucleotides and gene therapies with preserved molecular integrity and enhanced target engagement
  • Quantifying biodistribution shifts and pharmacodynamic effects following ultrasound-mediated BBB modulation in oncology and neurodegeneration
  • Positioning focused ultrasound within the broader CNS delivery toolkit alongside intrathecal dosing and receptor-mediated transport approaches

2:00 pm Effect of Extended Intracerebroventricular (ICV) Delivery on the Biodistribution of a Viral Vector in the CNS Of NHPs

Research Fellow, Drug Delivery Sciences, Abbvie
  • Achieving therapeutic levels in subcortical areas for the treatment of motor disorders is a daunting challenge in gene therapy
  • This study compares bolus versus extended intracerebroventricular (ICV) administration schedules for delivering AAV vectors in cynomolgus macaques. Using a stereotactically implanted infusion system, animals received the same total vector dose either as two quick infusions or as eight smaller infusions over four hours
  • The extended schedule led to greater gene expression in several brain regions, as well as peripheral tissues, suggesting that prolonged ICV infusion can enhance the distribution and expression of AAV-delivered genes in the CNS
  • These findings support further exploration of extended infusion protocols to improve AAV gene therapy

Track 2: Biology & Implementation

De-Risking CNS Delivery Through Better Dose Prediction & Toxicological Understanding

1:30 pm Dose Scaling from NHP to Human: PKPD Modelling & Safety Margin Determination

Independent Advisor, Stoke Therapeutics Inc.
  • Build physiologically-based pharmacokinetic models that account for CSF volume, turnover rates, and brain tissue penetration to improve dose predictions
  • Translate doses from non-human primates to humans using exposure-based rather than simple body weight scaling to improve safety margins
  • Integrate target engagement biomarkers and pharmacodynamic endpoints into models that predict efficacious human doses

2:00 pm Understanding Toxicological Liabilities of Intrathecal Oligos to Enable Safer CNS Delivery

Senior Director, Toxicology, Wave Life Sciences
  • Characterization of common CNS and off-target toxicological liabilities associated with intrathecal oligonucleotide delivery across preclinical models
  • Application of in vitro assay systems to predict and mechanistically understand CNS toxicity and support translational risk assessment
  • Integration of toxicology data into candidate selection frameworks to improve safety margins and de-risk direct CNS delivery approaches

2:30 pm Afternoon Break & Refreshments

Capital Allocation & Investment Trends in BBB Shuttles & Delivery Technologies

3:00 pm Panel Discussion: Direct vs Systemic Delivery: Driving Pharma Buy-In, Bottlenecks & Patient Perception

Senior Principal Scientist, UCB
Executive Director, Drug Delivery & Devices DDCS, Eli Lilly
Head of Device Clinical, Biogen
Head of IDU Device Development & Manufacturing, Biogen
Executive Director, Drug Delivery & Devices DDCS, Eli Lilly
  • Compare direct CNS delivery and systemic administration in terms of tissue exposure and selectivity, and their impact on target-site concentration, dose, and efficacy–toxicity balance
  • Evaluate translational challenges for direct delivery relative to systemic modalities, including device integration and demonstration of tissue-level pharmacological advantage
  • Explore how patient, clinician, and commercial perspectives shape trade-offs between invasiveness and the potential for improved efficacy and reduced toxicity through targeted delivery

3:30 pm Chair’s Closing Remarks

Senior Principal Scientist, UCB

3:35 pm End of Conference